from Yahoo Finance https://ift.tt/2YPIBzK
Author: therawinformant
-
If you don’t get more stimulus checks this summer from Uncle Sam, here’s how the stock market may react
-
Market outlook as Pfizer sparks coronavirus vaccine optimism
Tigress Financial Partners Chief Investment Officer Ivan Feinseth joins Yahoo Finance’s Zack Guzman to discuss his outlook on the markets as new Pfizer data sparks coronavirus vaccine optimism.from Yahoo Finance https://ift.tt/3gfnZqw
-
COVID SCIENCE-Blood cell damage may explain low oxygen levels; two vaccines show promise in early testing
from Yahoo Finance https://ift.tt/2BvGyI9
-
If You Own DuPont de Nemours (DD) Stock, Should You Sell It Now?
If you are looking for the best ideas for your portfolio you may want to consider some of Amana Mutual Funds top stock picks. Amana Mutual Funds, an investment management firm, is bullish on Dupont De Nemours Inc. (NYSE:DD) stock. In its Q4 2019 investor letter – you can download a copy here – the […]
from Yahoo Finance https://ift.tt/2NL5FcL
-
How To Weather A Global Recession Without Losing Your Wealth
There is investing in which you want to grow your wealth, and there is investing when you want to protect it. And during a global pandemic with the threat of a global recession looming, this is a good time to think about protection over profit. Though many people do make a fortune during uncertain financial Read More…
The post How To Weather A Global Recession Without Losing Your Wealth appeared first on Wall Street Survivor.
-
Has Inovio Stock Surged Enough for Now? This Analyst Says Yes
The frantic global search for a vaccine or therapy for the coronavirus has sent the valuations of previously small cap biotechs to unimagined heights over a short period of time. There can’t be many better examples for the phenomenon than Inovio Pharmaceuticals (INO). Investors have cheered the progress of its COVID-19 DNA vaccine candidate INO-4800 by sending shares on a mightily impressive run – the stock is up by 505% since the turn of the year (even after today's 25% sell off).The massive gains, the richly valued $3.2 billion market cap and a track record that – while promising – has yet to yield any significant results have prompted a rethink at investment firm H.C. Wainwright.“We believe the risk/reward ratio for Inovio has increased significantly as many open questions remain,” said firm analyst Ram Selvaraju, “Including the strength and duration of neutralizing antibodies and T cell responses that may be generated in human trials and the effective protection the vaccine may demonstrate in animal challenge studies.” “As a reminder,” concluded the 5-star analyst, “There is no approved human vaccine for any type of coronavirus, while no DNA vaccines have been approved for human use yet.”INO-4800 is currently in a Phase 1 trial with interim data expected any day now. A Phase 2/3 trial of INO-4800 is also planned to go ahead this summer. The company will need to demonstrate why its DNA based approach is “superior.” Proof Inovio can run the gamut from market authorization, to maintaining enough supply to pricing the vaccine reasonably while also driving profit, will also be required. Lastly, Selveraju says, Inovio’s offering will need to show “evidence that the immunity afforded by vaccination lasts sufficiently to have a significant impact on the spread of the coronavirus pandemic.”As these questions remain to be answered, Selvaraju slashed his rating on INO from Buy to Neutral, while removing his price target. (To watch Selvaraju’s track record, click here)Selveraju’s view is partially echoed by his colleagues across the Street, with 5 analysts saying Hold, and 3 suggesting Buy. Yet, the average price target of $26.50 implies 31% upside from current levels. (See Inovio stock-price forecast on TipRanks)To find good ideas for biotech stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
from Yahoo Finance https://ift.tt/3eTQGcq
-
EU in talks with Gilead to get remdesivir doses for EU countries
The European Commission said on Wednesday it was in negotiations with Gilead Sciences Inc to obtain doses of COVID-19 antiviral remdesivir for the 27 European Union countries. The Commission said it took note of the announcement that the United States had secured nearly all of Gilead’s projected production capacity for the next three months.
from Yahoo Finance https://ift.tt/2Vw05PF
-
June jobs report preview: Economists expect the US added 3 million payrolls, lowered unemployment rate
The U.S. economy is expected to have added millions more payrolls in June from May, as regions across the country eased social distancing restrictions and allowed more businesses to reopen.
from Yahoo Finance https://ift.tt/3iidXql
-
News On The Move: U.S. Air Force pilot killed in fighter jet crash, China arrests first person under new security law
Yahoo Finance’s Adam Shapiro breaks down Wednesday’s trending headlines.from Yahoo Finance https://ift.tt/3dPn8Lu
-
Here’s Why Apple (AAPL) Stock Could be a Solid ‘Buy’ in Today’s Market
If you are looking for the best ideas for your portfolio you may want to consider some of Amana Mutual Funds top stock picks. Amana Mutual Funds, an investment management firm, is bullish on Apple Inc. (NASDAQ:AAPL) stock. In its Q4 2019 investor letter – you can download a copy here – the firm discussed […]
from Yahoo Finance https://ift.tt/3ilmkBC